Published • loading... • Updated
Lilly’s experimental drug cuts weight by 21% in diabetes trial - Regional Media News
The 12 mg dose cut body weight by 20.8% and lowered A1C by up to 1.6% in adults with type 2 diabetes and obesity, Lilly said.
Summary by regionalmedianews.com
6 Articles
6 Articles
Lilly’s experimental drug cuts weight by 21% in diabetes trial - Regional Media News
Sept 29 (Reuters) - Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) [...]
Watauga Democrat+2 Reposted by 2 other sources
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity
·Calhoun, United States
Read Full Article
Retatrutide reaches 25% weight lost in phase 3. Bariatric surgery numbers, with an uncomfortable time detail. The article Confirmed: Retatrutide cuts 25% of weight in 80 weeks is taken from Future Next.
Coverage Details
Total News Sources6
Leaning Left2Leaning Right1Center2Last UpdatedBias Distribution40% Left, 40% Center
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
40% Center
L 40%
C 40%
R 20%
Factuality
To view factuality data please Upgrade to Premium
